> For the complete documentation index, see [llms.txt](https://www.thiamine.wiki/llms.txt). Markdown versions of documentation pages are available by appending `.md` to page URLs; this page is available as [Markdown](https://www.thiamine.wiki/biochemistry/tpp-synthesis.md).

# tpp synthesis

{% hint style="info" %}
**Section:** Complete Biochemistry → Coenzyme Pathways\
**Reading level:** Technical, with a plain-language summary\
**Last reviewed:** October 2026 · **Evidence status:** Well established
{% endhint %}

## Summary

Humans cannot build thiamine, but they can **activate** it. A single cytosolic enzyme, **thiamine pyrophosphokinase 1 (TPK1)**, transfers a pyrophosphate group from ATP to thiamine to make **thiamine pyrophosphate (TPP)**, also called thiamine diphosphate (ThDP). TPP is the coenzyme used by every thiamine-dependent enzyme. Because TPP is negatively charged, it cannot easily leave the cell, so phosphorylation also **traps** thiamine inside.

TPP needed in mitochondria is imported by a dedicated carrier, **SLC25A19**. TPP is gradually dephosphorylated to thiamine monophosphate (TMP) and free thiamine, and a small fraction is converted to thiamine triphosphate (ThTP). Inherited defects in TPK1 or SLC25A19 cause serious neurological disease.

## Key facts

| Property                           | Detail                                                                                      |
| ---------------------------------- | ------------------------------------------------------------------------------------------- |
| **Enzyme**                         | Thiamine pyrophosphokinase 1 (TPK1), EC 2.7.6.2                                             |
| **Reaction**                       | Thiamine + ATP → TPP + AMP (requires Mg²⁺)                                                  |
| **Mechanism**                      | Direct transfer of a pyrophosphate (diphosphate) group, not two sequential phosphorylations |
| **Location**                       | Cytosol                                                                                     |
| **Structure**                      | Homodimer; each subunit about 27 kDa                                                        |
| **Mitochondrial import**           | SLC25A19 (mitochondrial TPP carrier)                                                        |
| **Share of total thiamine as TPP** | Typically around 80–90% in mammalian tissues                                                |
| **Disorders**                      | TPK1 deficiency (THMD5); SLC25A19 defects (THMD3, THMD4)                                    |

## The TPK1 reaction

TPK1 binds thiamine and Mg-ATP and transfers the terminal pyrophosphate (β and γ phosphates) of ATP onto the hydroxyl group of thiamine's hydroxyethyl side chain, releasing AMP. Crystal structures of mammalian TPK show a dimer in which the thiamine-binding site lies at the subunit interface.

Several features are important:

* **Magnesium dependence:** the true substrate is Mg-ATP. Magnesium deficiency can impair TPP formation, which may explain case reports of thiamine deficiency that responded only after magnesium was corrected.
* **Substrate specificity:** TPK1 phosphorylates free thiamine but not TMP. It also phosphorylates certain analogues, including **pyrithiamine** and **oxythiamine**, converting them into inhibitory pyrophosphates. This is why these analogues are used to induce thiamine deficiency in research.
* **Low abundance:** TPK1 is expressed at low levels in most tissues, yet it is sufficient to keep enzymes saturated with TPP when thiamine supply is adequate.

## Where TPP goes in the cell

| Compartment               | TPP-dependent enzymes                                                                                                      | How TPP gets there                                                     |
| ------------------------- | -------------------------------------------------------------------------------------------------------------------------- | ---------------------------------------------------------------------- |
| **Cytosol**               | Transketolase                                                                                                              | Made locally by TPK1                                                   |
| **Mitochondrial matrix**  | Pyruvate dehydrogenase, α-ketoglutarate dehydrogenase, branched-chain α-ketoacid dehydrogenase, 2-oxoadipate dehydrogenase | Imported by **SLC25A19**, a member of the mitochondrial carrier family |
| **Peroxisomes**           | 2-Hydroxyacyl-CoA lyase 1 (HACL1)                                                                                          | Mechanism not fully established                                        |
| **Endoplasmic reticulum** | 2-Hydroxyacyl-CoA lyase 2 (HACL2/ILVBL)                                                                                    | Mechanism not fully established                                        |

Mitochondria hold a large fraction of cellular TPP. Mice lacking *Slc25a19* show mitochondrial TPP depletion, severe brain malformations and embryonic death, which demonstrates that cytosolic TPP cannot substitute for mitochondrial import.

Most TPP in cells is **bound to enzymes** rather than free. Binding of TPP also stabilizes several apoenzymes. In prolonged deficiency, some apoenzymes are lost. This is relevant to the interpretation of the erythrocyte transketolase test (see [Testing Limitations](broken://pages/1413ea1d53e19f9a39d0758ef8331327b1cf2bc4)).

## Interconversion of thiamine phosphate esters

| Step           | Enzyme(s)                                                     | Notes                                                                                                                               |
| -------------- | ------------------------------------------------------------- | ----------------------------------------------------------------------------------------------------------------------------------- |
| Thiamine → TPP | TPK1                                                          | The only route to TPP in animals                                                                                                    |
| TPP → TMP      | Thiamine pyrophosphatase activity                             | Enzymes not fully defined in mammals. "Thiamine pyrophosphatase" staining is a classic histochemical marker of the Golgi apparatus. |
| TMP → thiamine | Non-specific phosphatases (alkaline and acid phosphatases)    | TMP is a major phosphorylated form in plasma and cerebrospinal fluid                                                                |
| TPP → ThTP     | Mitochondrial F₀F₁-ATP synthase; cytosolic adenylate kinase 1 | Small pool; see [Thiamine Triphosphate](broken://pages/ccda4f125de058597405b11bf0fc0c63fa2d24ab)                                    |
| ThTP → TPP     | Specific 25-kDa thiamine triphosphatase (THTPA)               | Keeps ThTP levels low in most tissues                                                                                               |
| TPP → AThTP    | ThDP adenylyl transferase                                     | See [Adenosine Thiamine Triphosphate](broken://pages/85de8b9398347d5bef85c5cc8c28901823aeadbf)                                      |

### Typical distribution in mammalian tissues

| Form          | Approximate share of total thiamine                                |
| ------------- | ------------------------------------------------------------------ |
| TPP           | ≈80–90%                                                            |
| TMP           | ≈5–15%                                                             |
| Free thiamine | ≈5% or less                                                        |
| ThTP          | ≈0.1–1% (much higher in some tissues, such as pig skeletal muscle) |
| AThTP         | Trace                                                              |

Proportions vary by tissue, species and thiamine status. Human tissue biopsies show a broadly similar pattern.

## How microbes and plants make thiamine from scratch

Animals rely entirely on dietary thiamine because they lack the biosynthetic pathway present in bacteria, archaea, fungi and plants.

| Step               | Bacteria (e.g. *E. coli*, *B. subtilis*)                          | Yeast and plants                                                                  |
| ------------------ | ----------------------------------------------------------------- | --------------------------------------------------------------------------------- |
| Pyrimidine (HMP-P) | ThiC: complex radical rearrangement of an aminoimidazole ribotide | THI5/NMT1 (yeast) from histidine and pyridoxal phosphate; ThiC (plants)           |
| Thiazole           | ThiG, ThiH/ThiO, ThiS, ThiF and others                            | THI4: a "suicide" enzyme that donates its own cysteine sulfur and works only once |
| Coupling           | ThiE (TMP synthase) → TMP                                         | THI6 / TH1 → TMP                                                                  |
| Final activation   | ThiL phosphorylates TMP → TPP                                     | TMP dephosphorylated to thiamine, then TPK → TPP                                  |

### TPP riboswitches

In bacteria, fungi and plants, thiamine biosynthesis and transport genes are regulated by **TPP riboswitches**: RNA structures in messenger RNA that bind TPP directly and switch gene expression off when TPP is plentiful. This was one of the first riboswitch classes discovered. TPP riboswitches have not been found in animals. They are targets for antimicrobial research, and the thiamine analogue pyrithiamine kills some microbes partly by binding them.

## Disorders of TPP synthesis and distribution

| Disorder                                                                | Gene       | Main features                                                                                               | Response to thiamine                       |
| ----------------------------------------------------------------------- | ---------- | ----------------------------------------------------------------------------------------------------------- | ------------------------------------------ |
| **TPK1 deficiency** (THMD5)                                             | *TPK1*     | Episodic encephalopathy and ataxia, often triggered by infection; lactic acidosis; Leigh-like brain lesions | Variable; thiamine is used therapeutically |
| **Amish lethal microcephaly** (THMD3)                                   | *SLC25A19* | Severe congenital microcephaly, 2-ketoglutaric aciduria                                                     | Not responsive                             |
| **Bilateral striatal necrosis with progressive polyneuropathy** (THMD4) | *SLC25A19* | Episodic encephalopathy, striatal necrosis, neuropathy                                                      | Some reported responses                    |

In TPK1 deficiency, blood thiamine can be normal while tissue TPP is low. This is another example of why blood measurements do not always reflect cellular status.

## Factors that may impair TPP formation

| Factor                                                | Evidence                                                                                                |
| ----------------------------------------------------- | ------------------------------------------------------------------------------------------------------- |
| **Thiamine deficiency** (substrate shortage)          | Strong                                                                                                  |
| **Magnesium deficiency** (Mg-ATP is the co-substrate) | Biochemically established; clinical evidence from case reports                                          |
| **Alcohol**                                           | Experimental evidence of impaired phosphorylation; contributes alongside reduced absorption and storage |
| **Antagonists** (pyrithiamine, oxythiamine)           | Strong in experimental models                                                                           |
| **Genetic variants in&#x20;*****TPK1***               | Strong for rare severe mutations; unknown for common variants                                           |

## Evidence quality

| Claim type                                             | Strength                                                          |
| ------------------------------------------------------ | ----------------------------------------------------------------- |
| TPK1 reaction, structure, cytosolic location           | **Strong**                                                        |
| SLC25A19 as the mitochondrial TPP carrier              | **Strong**: genetic, cellular and knockout mouse evidence         |
| Identity of mammalian TPP- and TMP-hydrolysing enzymes | **Moderate**: activities established, specific enzymes less clear |
| Clinical significance of magnesium for TPP synthesis   | **Limited**: mechanistically sound, few clinical data             |

## Open questions

* How TPP reaches peroxisomes and the endoplasmic reticulum.
* Which enzymes dephosphorylate TPP and TMP in human cells, and whether they are regulated.
* Whether common *TPK1* or *SLC25A19* variants influence thiamine requirements.

## Related pages

* [TPP-Dependent Enzymes](broken://pages/48b61d9218e12eeb5f0e1876c67ae5de17b143ff)
* [Thiamine Transporters](broken://pages/e114cfc2a7f363a679ae103c52c9089e5d2d0b24)
* [Thiamine Triphosphate](broken://pages/ccda4f125de058597405b11bf0fc0c63fa2d24ab)
* [Thiamine Structure](broken://pages/e97e22d3de70d018c7c19aa407e5feb03d96c2a0)
* [How the Body Uses Thiamine](broken://pages/872a650978cf246c1fb7aaf4f07e0870abf2dab1)

## References

1. Timm DE, Liu J, Baker LJ, Harris RA. Crystal structure of thiamin pyrophosphokinase. *Journal of Molecular Biology*. 2001;310(1):195–204.
2. Lindhurst MJ, et al. Knockout of *Slc25a19* causes mitochondrial thiamine pyrophosphate depletion, embryonic lethality, CNS malformations, and anemia. *PNAS*. 2006;103(43):15927–15932.
3. Mayr JA, et al. Thiamine pyrophosphokinase deficiency in encephalopathic children with defects in the pyruvate oxidation pathway. *American Journal of Human Genetics*. 2011;89(6):806–812.
4. Rosenberg MJ, et al. Mutant deoxynucleotide carrier is associated with congenital microcephaly. *Nature Genetics*. 2002;32(1):175–178.
5. Spiegel R, et al. *SLC25A19* mutation as a cause of neuropathy and bilateral striatal necrosis. *Annals of Neurology*. 2009;66(3):419–424.
6. Gangolf M, et al. Thiamine status in humans and content of phosphorylated thiamine derivatives in biopsies and cultured cells. *PLoS One*. 2010;5(10):e13616.
7. Jurgenson CT, Begley TP, Ealick SE. The structural and biochemical foundations of thiamin biosynthesis. *Annual Review of Biochemistry*. 2009;78:569–603.
8. Chatterjee A, et al. *Saccharomyces cerevisiae* THI4p is a suicide thiamine thiazole synthase. *Nature*. 2011;478(7370):542–546.
9. Winkler W, Nahvi A, Breaker RR. Thiamine derivatives bind messenger RNAs directly to regulate bacterial gene expression. *Nature*. 2002;419(6910):952–956.
10. Sudarsan N, et al. Thiamine pyrophosphate riboswitches are targets for the antimicrobial compound pyrithiamine. *Chemistry & Biology*. 2005;12(12):1325–1335.
11. Dyckner T, et al. Aggravation of thiamine deficiency by magnesium depletion: a case report. *Acta Medica Scandinavica*. 1985;218(1):129–131.

{% hint style="info" %}
**Editorial note:** This page describes mechanisms and published evidence. It is not medical advice and does not recommend doses. Suggest corrections or new sources via the feedback link.
{% endhint %}
